Moderna’s shares surged dramatically on Wednesday after the biotechnology company and Merck announced positive results from a late-stage clinical trial of their personalized mRNA cancer vaccine.
The experimental treatment, intismeran autogene, was tested in combination with Merck’s immunotherapy Keytruda in patients with high-risk melanoma whose tumors had been surgically removed. The companies said the combination achieved statistically significant and clinically meaningful improvements in preventing the cancer from returning.
The Phase 3 study involved 1,137 patients with resected stage IIB to IV melanoma. The treatment met its primary goal of improving recurrence-free survival and also achieved a key secondary goal related to preventing cancer from spreading to distant parts of the body.
How does Moderna’s cancer vaccine work?
Unlike traditional preventive vaccines, this treatment is designed specifically for an individual patient after their tumor has been removed.
Researchers analyze genetic information from the patient’s tumor to identify mutations that could be recognized by the immune system. An individualized mRNA vaccine is then created to train the immune system to recognize and target cancer cells carrying those characteristics.
The approach is part of a broader effort to use mRNA technology not only for infectious diseases but also for personalized cancer treatment.
Why did Moderna stock jump?
Investors viewed the Phase 3 result as a major development because it provides evidence that Moderna’s mRNA technology could have applications beyond its COVID-19 vaccine business.
Moderna shares surged by more than 90% during trading, with reports putting the intraday gain substantially higher at certain points. Merck shares also rose following the announcement.
The result is particularly important for Moderna because the company has been working to diversify its pipeline as demand for its COVID-19 products has declined.
Is the cancer vaccine available now?
No. The vaccine is still an investigational treatment and is not yet an approved standard cancer therapy.
The companies have said they plan to engage with regulators following the Phase 3 results. More detailed clinical data are expected to be presented at a future medical meeting.
Moderna and Merck are also studying the personalized mRNA treatment in other cancers, including lung, bladder and kidney cancers.
What makes the results significant?
The development represents an important milestone for personalized cancer medicine. Earlier research had already shown encouraging long-term results: five-year follow-up from an earlier study found that the combination of intismeran autogene and pembrolizumab reduced the risk of melanoma recurrence or death by about 49% compared with pembrolizumab alone.
However, the latest Phase 3 announcement is particularly significant because it provides late-stage evidence supporting the personalized mRNA approach.
Scientists and investors are still waiting for the complete dataset, including detailed efficacy and safety results, before the treatment’s full potential can be assessed.
For Moderna, however, the announcement has already had a major impact on the stock market, with investors betting that successful cancer treatments could open a new and potentially lucrative chapter for the company.
